Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nastech Pharmaceutical Company, Inc.
Age
0–89
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal Female patients up to 89 years, inclusive;
BMI ≤ 35 kg/m2, inclusive;
In good health, determined by medical history and physical examination, as well as normal 12-lead ECG and vital signs;
Females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile (including tubal ligation, hysterectomy) for at least 3 months, until 30 days following Study Completion be willing to use an approved method of contraception;
Have a minimum of two evaluable non-fractured lumbar vertebrae.
Have low bone mineral density defined as having a T-score ≤ -2.0 as determined by DXA scan at either the lumbar spine (L1-L4) or total hip
You may not be if
Serious Medical Condition
History of diseases which affect bone metabolism other than postmenopausal osteoporosis such as Paget's disease, any secondary causes of osteoporosis, hypoparathyroidism, or hyperparathyroidism
Have a history of cancer within the past 5 years, except for basal cell carcinoma
Have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney stones or pre-existing hypercalciuria;
Have used any of the mostly commonly prescribed osteoporosis medications within 3 months of starting the investigational product, or for more than 1 month at any time within 6 months prior to starting investigational product.
Clareo Health | Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
